Conclusions and Recommendations Key messages for at-risk populations: The EVOKE trial failure does not invalidate GLP-1 agonists for preventionthe epidemiological signal remains strong, and these drugs may provide metabolic and cardiovascular benefits with potential cognitive co-benefits when used for approved indications SS-31s approval establishes precedent for mitochondrial-targeted therapeuticswatch this space for expanded indications Popular biohacker peptides (BPC-157, Dihexa, P21) have essentially no human cognitive evidence
VEGF's role in angiogenesis suggests GHK-Cu contributes to formation of vascular networks supporting hair follicle nutrition
CDMF version) [17, 18], Diabetes Complication Severity Index (DCSI) [19, 20], common comorbidities (yes/no), common concomitant drug classes (yes/no), diseases/conditions related to weight changes, medications associated with weight gain (yes/no), number of glucose-lowering medications, glucose-lowering drug class at baseline, common procedures (yes/no), number of all-cause hospitalizations (60 days before index date), number of all-cause emergency department visits (60 days before index date), baseline out-of-pocket costs for all prescription drugs, and number of follow-up days amid the COVID-19 pandemic (i.e., follow-up days after March 1, 2020)
Regmi, S., Fu, A., & Luo, K
